About china sxt pharmaceuticals - SXTC
China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.
SXTC At a Glance
China Sxt Pharmaceuticals, Inc.
178 Taidong North Road
Taizhou, Jiangsu 225300
| Phone | 86-523-86299087 | Revenue | 1.93M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,098,532.00 | |
| Sector | Health Technology | Employees | 75 | |
| Fiscal Year-end | 03 / 2025 | |||
| View SEC Filings |
SXTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.756 |
| Price to Book Ratio | 0.268 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 4.22 |
| Enterprise Value to Sales | -4.134 |
| Total Debt to Enterprise Value | -0.332 |
SXTC Efficiency
| Revenue/Employee | 25,713.293 |
| Income Per Employee | -41,313.76 |
| Receivables Turnover | 1.432 |
| Total Asset Turnover | 0.073 |
SXTC Liquidity
| Current Ratio | 1.599 |
| Quick Ratio | 1.508 |
| Cash Ratio | 1.357 |
SXTC Profitability
| Gross Margin | 28.726 |
| Operating Margin | -108.493 |
| Pretax Margin | -160.671 |
| Net Margin | -160.671 |
| Return on Assets | -11.763 |
| Return on Equity | -21.652 |
| Return on Total Capital | -18.691 |
| Return on Invested Capital | -21.163 |
SXTC Capital Structure
| Total Debt to Total Equity | 19.005 |
| Total Debt to Total Capital | 15.97 |
| Total Debt to Total Assets | 11.447 |
| Long-Term Debt to Equity | 2.115 |
| Long-Term Debt to Total Capital | 1.777 |